Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Oncology

Selected Works

2016

Melanoma

Articles 1 - 4 of 4

Full-Text Articles in Medicine and Health Sciences

Lifetime Prevalence Of Non-Melanoma And Melanoma Skin Cancer In Australia Surfers, James Furness, Mike Climstein, Wayne F. Hing, Joe Walsh Sep 2016

Lifetime Prevalence Of Non-Melanoma And Melanoma Skin Cancer In Australia Surfers, James Furness, Mike Climstein, Wayne F. Hing, Joe Walsh

Wayne Hing

Introduction

Surfing is one of the most popular aquatic activities in Australia with an estimated 2.7 million recreational surfers 1 however, Australia has long been recognized as having the highest incidence of melanoma in the world. As a result the expected risk of skin cancer in surfers due to long periods of exposure to ultraviolet radiation is of great concern 2. The aim of this study was to investigate the lifetime prevalence of non-melanoma skin cancers (NMSCs), (basal cell carcinoma (BCC), squamous cell carcinoma (SCC)), and melanoma skin cancers (MSCs) in Australian surfers.

Methods

Given the geographic distribution of surfers …


Lifetime Prevalence Of Non-Melanoma And Melanoma Skin Cancer In Australia Surfers, James Furness, Mike Climstein, Wayne F. Hing, Joe Walsh Sep 2016

Lifetime Prevalence Of Non-Melanoma And Melanoma Skin Cancer In Australia Surfers, James Furness, Mike Climstein, Wayne F. Hing, Joe Walsh

James Furness

Introduction

Surfing is one of the most popular aquatic activities in Australia with an estimated 2.7 million recreational surfers 1 however, Australia has long been recognized as having the highest incidence of melanoma in the world. As a result the expected risk of skin cancer in surfers due to long periods of exposure to ultraviolet radiation is of great concern 2. The aim of this study was to investigate the lifetime prevalence of non-melanoma skin cancers (NMSCs), (basal cell carcinoma (BCC), squamous cell carcinoma (SCC)), and melanoma skin cancers (MSCs) in Australian surfers.

Methods

Given the geographic distribution of surfers …


An Update On Braf Inhibitors And Other New Molecular Targets For The Treatment Of Malignant Melanoma Of The Skin, M. O. Faruk Khan, Carroll L. Ramos Aug 2016

An Update On Braf Inhibitors And Other New Molecular Targets For The Treatment Of Malignant Melanoma Of The Skin, M. O. Faruk Khan, Carroll L. Ramos

M. O. Faruk Khan

Malignant melanoma of the skin originates from mutations in melanocytes and can be lethal if unrecognized or untreated in its earlier stages. Deaths from melanoma are increasing in the United States and around the world every year. The available treatments produce low rates of response with modest survival impact. Among potential molecular targets under investigation, which are mostly in the tyrosine kinase pathway, the BRAF (V-raf murine sarcoma viral oncogene homolog B1) gene is the best studied and most frequently reported mutation in melanoma. The molecular targets for melanoma treatment, promising drugs for future melanoma treatment as well as the …


Primary Care For Melanoma: Should We Be Screaming For Screening?, Dennis J. Baumgardner, Alexandria Rogers Feb 2016

Primary Care For Melanoma: Should We Be Screaming For Screening?, Dennis J. Baumgardner, Alexandria Rogers

Dennis J. Baumgardner, MD

The incidence of cutaneous malignant melanoma continues to rise in the United States. This deadly disease is potentially curable if caught at an early stage, however screening programs remain controversial. The United States Preventive Services Task Force cites insufficient evidence to recommend screening, by total-body skin examination (TBSE), for early detection of cutaneous melanoma. While definitive studies may be cost-prohibitive in the United States, more recent evidence suggests that organized programs to increase TBSE reduce mortality from melanoma. The positive impact of TBSE, and education regarding risk reduction and skin self-examination, is most likely to be cost-effective in high-risk patients …